Inventor · disambiguated record
Jean-Marc Le Doussal
Also filed as: DOUSSAL JEAN-MARC LE · LE DOUSSAL JEAN-MARC
10 granted patents·7 pending applications·222 citations·filing 1987–2023
85Inventor score
Top patents by PatentIndex Score
17 records- 0194US5256395AAffinity enhancement immunological reagents for in vivo detection and killing of specific target cellsIMMUNOTECH PARTNERS·Filed 1987·Granted Oct 26, 1993·155 cites·25 claims
- 0280US5274076AHydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagentsIMMUNOTECH PARTNERS·Filed 1990·Granted Dec 28, 1993·62 cites·5 claims
- 0371US10745489B2Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancerOGD2 PHARMA·Filed 2018·Granted Aug 18, 2020·1 cites·12 claims
- 0469US11697689B2Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugsOGD2 PHARMA·Filed 2017·Granted Jul 11, 2023·1 cites·18 claims
- 0569US2023148349A1Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)OGD2 PHARMA·Filed 2022·Application pending·0 cites
- 0667US10611848B2Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activityOGD2 PHARMA·Filed 2014·Granted Apr 7, 2020·1 cites·23 claims
- 0767US10000575B2Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancerOGD2 PHARMA·Filed 2014·Granted Jun 19, 2018·2 cites·11 claims
- 0863US2023416398A1Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugsOGD2 PHARMA·Filed 2023·Application pending·0 cites
- 0959US11440968B2Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)OGD2 PHARMA·Filed 2017·Granted Sep 13, 2022·0 cites·21 claims
- 1057US2024190993A1New method to improve the anti-tumoral activity of macrophagesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1157US2024228659A1New method to improve nk cells cytotoxicityINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1256US2024142457A1Use of casd1 as a biomarker of a cancer expressing the o-acetylated-gd2 gangliosideOGD2 PHARMA·Filed 2022·Application pending·0 cites
- 1354US9566227B2Cosmetic composition comprising a muconopeptideACTIVEN·Filed 2013·Granted Feb 14, 2017·0 cites·3 claims
- 1445US10669328B2Human IgG1 derived antibody with pro-apoptotic activityOGD2 PHARMA·Filed 2014·Granted Jun 2, 2020·0 cites·25 claims
- 1540US2023018920A1Composition modulating botulinum neurotoxin effectFASTOX PHARMA SA·Filed 2020·Application pending·0 cites
- 1638US10149812B2Cosmetic composition comprising a muconopeptideACTIVEN·Filed 2016·Granted Dec 11, 2018·0 cites·11 claims
- 1738US2010105876A1Method for the oligomerisation of peptidesTERSKIKH ALEXEY·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jean-Marc Le Doussal files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →